Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against <i>Mycobacterium kansasii</i>

The incidence of infections with nontuberculous mycobacteria (NTM) has been increasing worldwide. The emergence of multidrug-resistant NTM is a serious clinical concern, and a vaccine for NTM has not yet been developed. We previously developed a new recombinant Bacillus Calmette–Guérin (rBCG) vaccin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shihoko Komine-Aizawa, Satoru Mizuno, Kazuhiro Matsuo, Takahiro Namiki, Satoshi Hayakawa, Mitsuo Honda
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	<i>Mycobacterium kansasii</i> CD8<sup>+</sup> T Cells CD4<sup>+</sup> T Cells recombinant BCG Medicine R
Acceso en línea:	https://doaj.org/article/077b4100a78f471f82f3c994dbe021c5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:077b4100a78f471f82f3c994dbe021c5
record_format	dspace
spelling	oai:doaj.org-article:077b4100a78f471f82f3c994dbe021c52021-11-25T19:10:39ZRecombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against <i>Mycobacterium kansasii</i>10.3390/vaccines91112602076-393Xhttps://doaj.org/article/077b4100a78f471f82f3c994dbe021c52021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1260https://doaj.org/toc/2076-393XThe incidence of infections with nontuberculous mycobacteria (NTM) has been increasing worldwide. The emergence of multidrug-resistant NTM is a serious clinical concern, and a vaccine for NTM has not yet been developed. We previously developed a new recombinant Bacillus Calmette–Guérin (rBCG) vaccine encoding the antigen 85B (Ag85B) protein of <i>Mycobacterium kansasii</i>—termed rBCG-Mkan85B—which was used together with a booster immunization with plasmid DNA expressing the same <i>M. kansasii</i> Ag85B gene (DNA-Mkan85B). We reported that rBCG-Mkan85B/DNA-Mkan85B prime–boost immunization elicited various NTM strain-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells and induced <i>Mycobacterium</i> <i>tuberculosis</i>-specific immunity. In this study, to investigate the protective effect against <i>M. kansasii</i> infection, we challenged mice vaccinated with a rBCG-Mkan85B or rBCG-Mkan85B/DNA-Mkan85B prime–boost strategy with virulent <i>M. kansasii</i>. Although BCG and rBCG-Mkan85B immunization each suppressed the growth of <i>M. kansasii</i> in the mouse lungs, the rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination reduced the bacterial burden more significantly. Moreover, the rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination induced antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Our data suggest that rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination effectively enhances antigen-specific T cells. Our novel rBCG could be a potential alternative to clinical BCG for preventing various NTM infections.Shihoko Komine-AizawaSatoru MizunoKazuhiro MatsuoTakahiro NamikiSatoshi HayakawaMitsuo HondaMDPI AGarticle<i>Mycobacterium kansasii</i>CD8<sup>+</sup> T CellsCD4<sup>+</sup> T Cellsrecombinant BCGMedicineRENVaccines, Vol 9, Iss 1260, p 1260 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	<i>Mycobacterium kansasii</i> CD8<sup>+</sup> T Cells CD4<sup>+</sup> T Cells recombinant BCG Medicine R
spellingShingle	<i>Mycobacterium kansasii</i> CD8<sup>+</sup> T Cells CD4<sup>+</sup> T Cells recombinant BCG Medicine R Shihoko Komine-Aizawa Satoru Mizuno Kazuhiro Matsuo Takahiro Namiki Satoshi Hayakawa Mitsuo Honda Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against <i>Mycobacterium kansasii</i>
description	The incidence of infections with nontuberculous mycobacteria (NTM) has been increasing worldwide. The emergence of multidrug-resistant NTM is a serious clinical concern, and a vaccine for NTM has not yet been developed. We previously developed a new recombinant Bacillus Calmette–Guérin (rBCG) vaccine encoding the antigen 85B (Ag85B) protein of <i>Mycobacterium kansasii</i>—termed rBCG-Mkan85B—which was used together with a booster immunization with plasmid DNA expressing the same <i>M. kansasii</i> Ag85B gene (DNA-Mkan85B). We reported that rBCG-Mkan85B/DNA-Mkan85B prime–boost immunization elicited various NTM strain-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells and induced <i>Mycobacterium</i> <i>tuberculosis</i>-specific immunity. In this study, to investigate the protective effect against <i>M. kansasii</i> infection, we challenged mice vaccinated with a rBCG-Mkan85B or rBCG-Mkan85B/DNA-Mkan85B prime–boost strategy with virulent <i>M. kansasii</i>. Although BCG and rBCG-Mkan85B immunization each suppressed the growth of <i>M. kansasii</i> in the mouse lungs, the rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination reduced the bacterial burden more significantly. Moreover, the rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination induced antigen-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells. Our data suggest that rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination effectively enhances antigen-specific T cells. Our novel rBCG could be a potential alternative to clinical BCG for preventing various NTM infections.
format	article
author	Shihoko Komine-Aizawa Satoru Mizuno Kazuhiro Matsuo Takahiro Namiki Satoshi Hayakawa Mitsuo Honda
author_facet	Shihoko Komine-Aizawa Satoru Mizuno Kazuhiro Matsuo Takahiro Namiki Satoshi Hayakawa Mitsuo Honda
author_sort	Shihoko Komine-Aizawa
title	Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against <i>Mycobacterium kansasii</i>
title_short	Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against <i>Mycobacterium kansasii</i>
title_full	Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against <i>Mycobacterium kansasii</i>
title_fullStr	Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against <i>Mycobacterium kansasii</i>
title_full_unstemmed	Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against <i>Mycobacterium kansasii</i>
title_sort	recombinant bcg-prime and dna-boost immunization confers mice with enhanced protection against <i>mycobacterium kansasii</i>
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/077b4100a78f471f82f3c994dbe021c5
work_keys_str_mv	AT shihokokomineaizawa recombinantbcgprimeanddnaboostimmunizationconfersmicewithenhancedprotectionagainstimycobacteriumkansasiii AT satorumizuno recombinantbcgprimeanddnaboostimmunizationconfersmicewithenhancedprotectionagainstimycobacteriumkansasiii AT kazuhiromatsuo recombinantbcgprimeanddnaboostimmunizationconfersmicewithenhancedprotectionagainstimycobacteriumkansasiii AT takahironamiki recombinantbcgprimeanddnaboostimmunizationconfersmicewithenhancedprotectionagainstimycobacteriumkansasiii AT satoshihayakawa recombinantbcgprimeanddnaboostimmunizationconfersmicewithenhancedprotectionagainstimycobacteriumkansasiii AT mitsuohonda recombinantbcgprimeanddnaboostimmunizationconfersmicewithenhancedprotectionagainstimycobacteriumkansasiii
_version_	1718410195525173248

Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against <i>Mycobacterium kansasii</i>

Ejemplares similares